Drugs / RSV mRNA vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07418229 | Mar → Jun 2026 overdue | respiratory syncytial virus infectious disease | Sinovac Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV mRNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07418229 ↗ |
| Modality | Messenger RNA (mRNA) | “RSV mRNA vaccine” NCT07418229 ↗ |